Nancy A Dawson

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. doi request reprint Sipuleucel-T and immunotherapy in the treatment of prostate cancer
    Nancy A Dawson
    Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center Podium B, Division of Hematology Oncology, Department of Medicine, Genitourinary Oncology Program, 3800 Reservoir Road NW, Washington, DC 20007, USA 1 202 444 9094 1 202 444 9429
    Expert Opin Biol Ther 14:709-19. 2014
  2. doi request reprint Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy
    Nancy A Dawson
    Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Expert Rev Anticancer Ther 9:953-62. 2009
  3. ncbi request reprint Epothilones in prostate cancer: review of clinical experience
    N A Dawson
    Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Ann Oncol 18:v22-7. 2007
  4. doi request reprint A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004
    Nancy A Dawson
    Georgetown University Medical Center, Washington, DC 20007 2113 USA
    Clin Genitourin Cancer 6:110-6. 2008
  5. pmc Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
    Leonard N Chen
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:58. 2013
  6. pmc Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study
    Tanya B Dorff
    Department of Medicine, Division of Medical Oncology, Genitourinary Cancers, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 29:2040-5. 2011
  7. pmc Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
    Eric K Oermann
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
    J Hematol Oncol 4:12. 2011
  8. doi request reprint Update on castrate-resistant prostate cancer: 2010
    Kiran Lassi
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, District of Columbia 20007, USA
    Curr Opin Oncol 22:263-7. 2010
  9. doi request reprint Emerging therapies in castrate-resistant prostate cancer
    Kiran Lassi
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, District of Columbia, USA
    Curr Opin Oncol 21:260-5. 2009
  10. doi request reprint Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives
    Kiran Lassi
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA
    Future Oncol 7:551-8. 2011

Collaborators

Detail Information

Publications17

  1. doi request reprint Sipuleucel-T and immunotherapy in the treatment of prostate cancer
    Nancy A Dawson
    Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center Podium B, Division of Hematology Oncology, Department of Medicine, Genitourinary Oncology Program, 3800 Reservoir Road NW, Washington, DC 20007, USA 1 202 444 9094 1 202 444 9429
    Expert Opin Biol Ther 14:709-19. 2014
    ....
  2. doi request reprint Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy
    Nancy A Dawson
    Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Expert Rev Anticancer Ther 9:953-62. 2009
    ..For high-risk patients, the focus is on multimodality approaches, especially the addition of chemotherapy. Recent developments in radiation therapy and adjuvant chemotherapy are the focus of this review...
  3. ncbi request reprint Epothilones in prostate cancer: review of clinical experience
    N A Dawson
    Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Ann Oncol 18:v22-7. 2007
    ..The epothilones are potent antimicrotubule agents that have demonstrated activity in the setting of taxane resistance. They are structurally distinct compounds that appear to lack cross-resistance with the taxanes...
  4. doi request reprint A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004
    Nancy A Dawson
    Georgetown University Medical Center, Washington, DC 20007 2113 USA
    Clin Genitourin Cancer 6:110-6. 2008
    ..A phase II study was conducted to assess the safety and efficacy of docetaxel/estramustine combined with exisulind, an apoptotic antineoplastic drug...
  5. pmc Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
    Leonard N Chen
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:58. 2013
    ..We report our early experience using SBRT for localized prostate cancer...
  6. pmc Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study
    Tanya B Dorff
    Department of Medicine, Division of Medical Oncology, Genitourinary Cancers, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 29:2040-5. 2011
    ..Men with high-risk features (extraprostatic extension or high Gleason grade) face a high risk of prostate cancer recurrence after radical prostatectomy. Clinical trials of adjuvant systemic therapy for such patients have been limited...
  7. pmc Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
    Eric K Oermann
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
    J Hematol Oncol 4:12. 2011
    ..We report on our early experience with CyberKnife SBRT for low- to intermediate-risk prostate cancer patients and assess the rate of inducing biochemical and clinical hypogonadism...
  8. doi request reprint Update on castrate-resistant prostate cancer: 2010
    Kiran Lassi
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, District of Columbia 20007, USA
    Curr Opin Oncol 22:263-7. 2010
    ....
  9. doi request reprint Emerging therapies in castrate-resistant prostate cancer
    Kiran Lassi
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, District of Columbia, USA
    Curr Opin Oncol 21:260-5. 2009
    ....
  10. doi request reprint Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives
    Kiran Lassi
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA
    Future Oncol 7:551-8. 2011
    ..This article reviews current data on the novel therapeutics demonstrating activity in metastatic castration-resistant prostate cancer and their future role in the treatment of this disease with a poor prognosis...
  11. ncbi request reprint Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer
    Nancy A Dawson
    Genitourinary Oncology Program, Greenebaum Cancer Institute, University of Maryland, Baltimore, Maryland 21201, USA
    Urology 62:102-18. 2003
    ..Patients enrolling in these trials need to be clearly informed of the limited expectations of these novel exploratory approaches...
  12. ncbi request reprint A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer
    Eric K Oermann
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
    Technol Cancer Res Treat 9:453-62. 2010
    ..Early results are encouraging with biochemical response and acceptable toxicity. These data provide a basis for the design of a phase II clinical trial...
  13. ncbi request reprint Intermittent androgen deprivation
    N A Dawson
    Division of Hematology Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201 1595, USA
    Curr Oncol Rep 2:409-16. 2000
    ..Final analyses of these critical trials will define the ultimate role of this approach in prostate cancer. In the interim, intermittent androgen deprivation should be considered an experimental approach...
  14. ncbi request reprint Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials
    N A Dawson
    Hematology Oncology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    J Clin Oncol 16:3398-405. 1998
    ..To survey eligibility and response criteria for clinical trials in hormone-refractory prostate cancer (HRPC)...
  15. ncbi request reprint Treatment of progressive metastatic prostate cancer
    N A Dawson
    Hematology Oncology Service, Walter Reed Army Medical Center, Washington, DC
    Oncology (Williston Park) 7:17-24, 27; discussion 27-9. 1993
    ..Quality-of-life issues should be integrated into all clinical trials involving hormone-refractory metastatic prostate cancer...
  16. pmc Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer
    R C Bergan
    Department of Cell and Cancer Biology, National Cancer Institute, Bethesda, Maryland, USA
    J Natl Med Assoc 89:622-8. 1997
    ..These findings are consistent with the hypothesis that therapies that work through mechanisms independent of the androgen receptor may result in similar outcomes across ethnic groups...
  17. ncbi request reprint The management of localized prostate cancer
    N A Dawson
    Genito Urinary Medical Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201 1595, USA
    Prostate Cancer Prostatic Dis 5:S3-7. 2002
    ..The doctor and patient must together decide the appropriate treatment for him and his tumor...